Macular Degeneration

Macular degeneration, or age-related macular degeneration (AMD), is a leading cause of vision loss in Americans 60 and older. It is a disease that destroys your sharp, central vision.

Programs + Services


Ophthalmology (New England Eye Center)

Ophthalmology (New England Eye Center) at Tufts Medical Center in Boston specializes in the testing and treatment of all types of eye diseases and visual problems.
More information about programs and services

Doctors + Care Team

Andre J. Witkin, MD

Andre J. Witkin, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Ophthalmologist; Retina Specialist; Assistant Professor, Tufts University School of Medicine
Department(s): Ophthalmology
Appt. Phone: 617-636-4600
Fax #: 617-636-4866

Vitreoretinal surgery, retinal and macular disorders

View Full Profile for Andre J. Witkin, MD

Research + Clinical Trials


Non Exudative Age-Related Macular Degeneration Imaged with Swept Source Optical Coherence Tomography

This is a longitudinal observational study that will look at 300 subjects, 200 with intermediate AMD in at least one eye, or with AMD in one eye, either early or intermediate, and with late AMD (exudative) in the other eye, and 100 subjects with nGA or GA in at least one eye.

 

The target population is all subjects who are at least 50 years of age and have a clinical diagnosis of non-exudative AMD in at least one eye.

Subjects who convert to exudative AMD during the study will be treated as per the enrolling physician’s standard of care and will continue to be scanned per protocol, allowing for a wider interval of +/- 30 days around the standard timing of scanning to avoid excessively frequent visits.
More information about research and clinical trials


A PHASE IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF THE RESPONSE TO TREATMENT AFTER TRANSITION TO THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB (SUSVIMOTM [RANIBIZUMAB INJECTION]) IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PREVIOUSLY TREATED WITH INTRAVITREAL AGENTS OTHER THAN RANIBIZUMAB

This study is a Phase IV multicenter, open-label (BCVA assessor-masked) study designed to assess the response to treatment with SUSVIMO every 24 weeks in patients with Neovascular Age-Related Macular Degeneration (nAMD) who have been previously treated with anti-VEGF agents other than ranibizumab.
More information about research and clinical trials